(Q35587196)

9 August 2017

1 reference

title

Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies (English)

1 reference

9 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Cardiology and cardiovascular medicine

3 April 2024

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

3 April 2024

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

3 April 2024

1

Jean-Claude Tardif

1 reference

9 August 2017

Jean Grégoire

2

1 reference

9 August 2017

Marc-André Lavoie

3

1 reference

9 August 2017

Philippe L. L'Allier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624139

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14624139

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

https://journals.lww.com/00041433-200312000-00010

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Current Opinion in Lipidology

3 April 2024

published in

1 reference

9 August 2017

14

1 reference

9 August 2017

6

1 reference

9 August 2017

615-620

1 reference

Systemic drug therapy for restenosis: "déjà vu all over again".

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Prevention of restenosis with antioxidants: mechanisms and implications

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Inflammation and restenosis in the stent era.

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Probucol promotes functional reendothelialization in balloon-injured rabbit aortas

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Prevention of restenosis after angioplasty in small coronary arteries with probucol

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Antioxidants and prevention of restenosis after directional coronary atherectomy

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Clinical results with AGI-1067: a novel antioxidant vascular protectant

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Late T-lymphocyte and monocyte activation in coronary restenosis. Evidence for a persistent inflammatory/immune mechanism?

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effect of statin therapy on restenosis after coronary stent implantation

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Italian heart journal : official journal of the Italian Federation of Cardiology

3 April 2024

39

3

455

Prati

2002

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Relation of homocysteine, vitamin B(12), and folate to coronary in-stent restenosis

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Total plasma homocysteine and restenosis after percutaneous coronary angioplasty: current evidence

3 April 2024

45

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effect of Homocysteine-Lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2).

3 April 2024

49

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial

3 April 2024

50

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Pilot trial of oral rapamycin for recalcitrant restenosis

3 April 2024

51

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Oral everolimus inhibits in-stent neointimal growth

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Sarpogrelate treatment reduces restenosis after coronary stenting

3 April 2024

53

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-stent restenosis model

3 April 2024

54

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Ramatroban, a thromboxane A2 receptor antagonist, prevents macrophage accumulation and neointimal formation after balloon arterial injury in cholesterol-fed rabbits

3 April 2024

55

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

3 April 2024

56

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Usefulness of endothelin(A) receptor antagonists for the prevention of in-stent restenosis in patients with stable angina pectoris or silent myocardial ischemia

3 April 2024

57

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Metoprolol treatment to prevent restenosis following percutaneous transluminal coronary angioplasty

3 April 2024

58

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization

3 April 2024

59

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty

3 April 2024

60

1 reference

https://api.crossref.org/works/10.1097/00041433-200312000-00010

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference